From: Early changes in gene expression profiles in AML patients during induction chemotherapy
Patient ID | Year of diagnosis | Age | Induction treatment regime | Blast count at baseline | Leukocyte paticle count at baseline (× 109/L) | Leukocyte particle count Day 2 (48 h) (× 109/L) | Cytogenetics | FLT3- ITD | NPM1 mutation | CEBPA mutation | Morphological complete remission after inductionc |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2001 | 67 | Idarubicin and cytarabine | 80% (BM), 60% (PB) | 60,8 | 58 | Aberrant expression of T-cell markers | NA | NA | NA | No |
2 | 2001 | 81 | Daunorubicin and cytarabinea | NA | 93 | 75,9 | NA | NA | NA | NA | Yes |
3 | 2003 | 39 | Daunorubicin and cytarabinea | 20% (PB) | 51,7 | 31,6 | Normal karyotype | No | No | NA | Yes |
4 | 2001 | 67 | Cladribine, cytarabine and idarubicin | 90% (BM) | 72 | 1,9* | Trisomy 8 | NA | NA | NA | Yes |
5 | 2003 | 66 | Daunorubicin and low-dose cytarabineb | 40% (BM) | 35,8 | 11,2 | 1-40dmin [22] /46XY [3] | Yes | No | NA | No |
6 | 2015 | 64 | Daunorubicin and cytarabine | 78% (BM), 57% (PB) | 1,6 | 0,7 | Normal karyotype | No | Yes | Heterozygous | Yes |
7 | 2015 | 74 | Daunorubicin and cytarabine | 88% (BM) | 164 | 2,6 | Not possible due to no mitoses after culturing | NA | NA | NA | No |
8 | 2015 | 73 | Daunorubicin and cytarabine | 60% (BM), 77% (PB) | 135 | 37 | Normal karyotype | Yes | No | No | No |
9 | 2016 | 21 | Daunorubicin and cytarabine | 75% (BM), 44% (PB) | 68 | 5,2 | 47XY, inv.(16)(p13;q22), +mar [23] | No | No | NA | Yes |
10 | 2016 | 46 | Daunorubicin and cytarabine | 32% (BM), 2% (PB) | 7,4 | 3,4 | Complex karyotype | No | No | No | No |